* clinical signs indicative of severe covid-19 * rapidly progressive covid-19 which is likely to progress to "severe" within 24 hours * documented infection other than covid-19 * any medical condition that, in the investigator's opinion, could adversely impact safety * pregnant or lactating women * has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, monoclonal antibodies (mabs) against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit. note: participants who have been prescribed hydroxychloroquine or chloroquine with or without azithromycin or other approved products for the off-label treatment of covid-19 prior to study enrollment may be included and may continue to receive these agents so long as the dose remains stable. additionally, any approved or authorized treatment (e.g., remdesivir, dexamethasone or treatments approved under an emergency use authorization) is allowed.

* clinical signs indicative of severe covid-19 * rapidly progressive covid-19 which is likely to progress to "severe" within 24 hours * documented infection other than covid-19 * any medical condition that, in the investigator's opinion, could adversely impact safety * pregnant or lactating women * has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, monoclonal antibodies (mabs) against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit. note: participants who have been prescribed hydroxychloroquine or chloroquine with or without azithromycin or other approved products for the off-label treatment of covid-19 prior to study enrollment may be included and may continue to receive these agents so long as the dose remains stable. additionally, any approved or authorized treatment (e.g., remdesivir, dexamethasone or treatments approved under an emergency use authorization) is allowed.

- clinical signs indicative of severe covid-19 - rapidly progressive covid-19 which is likely to progress to "severe" within 24 hours - documented infection other than covid-19 - any medical condition that, in the investigator's opinion, could adversely impact safety - pregnant or lactating women - has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, monoclonal antibodies (mabs) against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit. note: participants who have been prescribed hydroxychloroquine or chloroquine with or without azithromycin or other approved products for the off-label treatment of covid-19 prior to study enrollment may be included and may continue to receive these agents so long as the dose remains stable. additionally, any approved or authorized treatment (e.g., remdesivir, dexamethasone or treatments approved under an emergency use authorization) is allowed.

- clinical signs indicative of severe covid-19 - rapidly progressive covid-19 which is likely to progress to "severe" within 24 hours - documented infection other than covid-19 - any medical condition that, in the investigator's opinion, could adversely impact safety - pregnant or lactating women - has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, monoclonal antibodies (mabs) against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit. note: participants who have been prescribed hydroxychloroquine or chloroquine with or without azithromycin or other approved products for the off-label treatment of covid-19 prior to study enrollment may be included and may continue to receive these agents so long as the dose remains stable. additionally, any approved or authorized treatment (e.g., remdesivir, dexamethasone or treatments approved under an emergency use authorization) is allowed.